| famuyiyaob | Дата: Понедельник, 29.12.2014, 23:00 | Сообщение # 1 |
|
Группа: Гости
| Tamoxifen is an antagonist of the estrogen receptor in chest tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and for this may be characterized as a conflicting agonist/antagonist. Tamoxifen is the everyday endocrine (anti-estrogen) treatment benefit of hormone receptor-positive bust cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also oftentimes employed in that setting.[1 -
Some tit cancer cells call for estrogen to grow. Estrogen binds to and activates the estrogen receptor in these cells. Tamoxifen is metabolized into compounds that also tie up to the estrogen receptor but do not activate it. Because of this competitive hostility, tamoxifen acts like a opener in disrepair dippy in the keep track of exclude that prevents any other cue from being inserted, preventing estrogen from binding to its receptor. Ergo bosom cancer chamber spread is blocked.
Tamoxifen was discovered near pharmaceutical company Royal Chemical Industries[2 - (now AstraZeneca) and is sold beneath the traffic names Nolvadex, Istubal, and Valodex. After all, the hypnotic, unvarying in the past its grant ending, was and still is extremely referred to via its generic term "tamoxifen."
Medical uses
Heart of hearts cancer
Tamoxifen is currently in use accustomed to with a view the treatment of both at and advanced ER+ (estrogen receptor explicit) boob cancer in pre- and post-menopausal women.[3 - Additionally, it is the most unrefined hormone treatment instead of male mamma cancer.[4 - It is also approved away the FDA quest of the forestalling of tit cancer in women at high risk of developing the disease.[5 - It has been further approved in the direction of the reduction of contralateral (in the irreconcilable bosom) cancer.
In 2006, the large STAR clinical about concluded that raloxifene is equally powerful in reducing the amount of core cancer, but after an for the most part 4-year follow-up there were 36% fewer uterine cancers and 29% fewer blood clots in women engaging raloxifene than in women taking tamoxifen, although the diversity is not statistically significant.[6 - [7 - [8 -
In 2005, the ATAC contest showed that after unexceptional 68 months following a 5 year adjuvant treatment, the group that receivedanastrozole (Arimidex) had significantly better results than the tamoxifen assemblage in measures like condition uninhibited survival, but no overall mortality benefit.[9 - Facts from the tentative intimate that anastrozole should be the preferred medication to save postmenopausal women with localized tit cancer that is estrogen receptor (ER) positive.[10 - Another study develop that the risk of recurrence was reduced 40% (with some gamble of bone cleavage) and that ER anti patients also benefited from switching to anastrozole.[11 - [12 -
From http://www.fmyykj.com - suzhou pharmaceutical technology co.,ltd.
|
| |
| |
